Global Zonisamide Market Size, Share and Trends Analysis Report, By Type (25mg, 50 mg, and 100mg), By Condition (Epilepsy and Parkinson’s Disease) By Application (Adult, Pediatric, and Geriatric), Forecast Period (2022-2028)

The global zonisamide market is anticipated to grow at a CAGR of 2.2% during the forecast period (2022-2028). With the rising cases of epilepsy across the globe the demand for zonisamide is increasing. Epilepsy is a brain condition that affects people of all ages and is a chronic non-communicable disease. For instance, in 2021 According to WHO, Epilepsy affects an estimated 5 million people globally each year. Epilepsy is projected to affect 49 out of every 100,000 people in high-income nations each year. This rate can be as high as 139 per 100,000 in low- and middle-income nations. The cases of abnormal, premature deliveries increased due to which the cases of epilepsy increased. The initial dosage is less however with the increase in age and weight of a person the dosage also increases, and it is a long course of treatment that will rise the zonisamide market.

 

Certain forms of seizures are treated with zonisamide in combination with other drugs. Zonisamide belongs to the anticonvulsant class of drugs. It works by reducing aberrant brain electrical activity. For instance, Sun Pharmaceutical Industries Ltd. Offers Zonisep 100 capsules in three strengths, it’s an anti-epileptic drug that’s used to treat seizures in people who have epilepsy. Zonisep 100 Capsule reduces the speed with which electrical signals in the brain induce seizures (fits). It can also help with symptoms including bewilderment, jerking movements that are out of control, loss of awareness, and fear or worry.

 

In order to maintain in the competition, companies are getting licenses to manufacture zonisamide under their name. For instance, in June 2021 Eisai Co., Ltd. has announced that it has reached a deal with Advanz Pharma to sell its antiepileptic drug Zonegran in Europe, the Middle East, Russia, and Australia. With the increasing population base and rising diseases, the Asia-Pacific region is anticipated to holds a prominent share in the market in the forecast period. Currently, with the advanced healthcare system, facilities, and policies, North America is in a major region where zonisamide is being used for the treatment of epilepsy across the globe.

 

Some major players in the market include Eisai Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. Zydus Pharmaceuticals, Inc. offers Epigran 100mg capsules, It’s an anti-epileptic drug that’s used to treat seizures in people who have epilepsy. It can be used alone or in combination with other medications to treat adults and children. It aids in the prevention of seizures that impact a portion of the entire brain.

 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Type
  • By Condition
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
  • Competitive Landscape– Eisai Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals, Inc., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Zonisamide Market Report by Segment

By Type

• 25mg
• 50mg
• 100mg

 By Condition

• Epilepsy
• Parkinson’s Disease

By Application

• Adult
• Pediatric
• Geriatric

Global Zonisamide Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa